Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 6/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18332163 | 0.97 | HRH3 (0.41) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL10003089 | 0.91 | PTGDR2 (0.39) | PTGDR2LMNAALOX5NOD2NOD1 | |
| SCHEMBL10003016 | 0.90 | HRH3 (0.40) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL10004348 | 0.86 | HRH3 (0.43) | HRH3LMNAGAAALOX5NOD2 | |
| SCHEMBL10004969 | 0.85 | NOD2 (0.54) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL18332121 | 0.84 | HRH3 (0.40) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL10003201 | 0.83 | HRH3 (0.39) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL11931671 | 0.83 | HRH3 (0.39) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL10003199 | 0.83 | HRH3 (0.39) | HRH3PTGDR2LMNAGAAALOX5 | |
| SCHEMBL18332167 | 0.81 | HRH3 (0.47) | HRH3PTGDR2LMNAGAAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471786-B1 | AMINOPYRAZOLE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2471786-A1 | AMINOPYRAZOLE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | HRH3 76/4885PTGDR2 1849/4885LMNA 4775/4885 |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 | HRH3 30/4885PTGDR2 1382/4885LMNA 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.